semaglutide by novo nordisk cuts Wegovy price up to 37% in India Novo Nordisk wins FDA approval

This 5-year follow-up to the STAMPEDE clinical trial randomized patients with T2DM to RYGB, VSG or medical management, and showed that RYGB and VSG were superior to medical therapy in terms of weight loss, glycaemic control and reduction in medication use

2022 Jan-

Injectable semaglutide at equivalent therapeutic doses (2.4mg weekly Wegovy) produces average weight loss of 14.9% over 68 weeks in clinical trials

Additional research in the Journal of Animal Science showed that glycine increased protein synthesis rates by 20 to 80% and inhibited protein degradation rates by 15 to 30% in a concentration-dependent manner